Type 2 Diabetes Clinical Trial
— DiaWebOfficial title:
Assessment of a Web-based Guided Self-Determination Intervention for Adults With Type 2 Diabetes in General Practice
The overall aim of this study is to assess the effectiveness of a web-based Guided Self-Determination program among adults with type 2 diabetes in general practice in order to improve diabetes self-management behaviours and HbA1c through enhanced patient activation, self-care competence, and autonomy.
Status | Not yet recruiting |
Enrollment | 172 |
Est. completion date | January 1, 2020 |
Est. primary completion date | September 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Type 2 diabetes of duration = 3 months - Ability to communicate in Norwegian - Access to the internet and bank ID Exclusion Criteria: - Patients with cognitive impairment - Patients with severe co-morbidity |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Stavanger | Bergen University College |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Patient Activation Measure (PAM) | Assessing change between three time points: Change from baseline at 12-16 weeks, and change from 12- 16 weeks at 6 months | ||
Secondary | The Health Care Climate Questionnaire (HCCQ) | Assessing change between three time points: Change from baseline at 12- 16 weeks, and change from 12- 16 weeks at 6 months | ||
Secondary | Perceived Competence for Diabetes Scale (PCDS) | Assessing change between three time points: Change from baseline at 12- 16 weeks, and change from 12- 16 weeks at 6 months | ||
Secondary | Treatment Self-Regulation (TSRQ) | At three time points: at baseline, 12-16 weeks later at the end of the intervention and six months after finishing the intervention. | ||
Secondary | Diabetes Management Self-efficacy Scale (SE-type 2 diabetes) | Assessing change between three time points: Change from baseline at 12-16 weeks, and change from 12-16 weeks at 6 months | ||
Secondary | Summary of diabetes self-care activities (SDSCA) | Assessing change between three time points: Change from baseline at 12-16 weeks, and change from 12-16 weeks at 6 months | ||
Secondary | The WHO 5-item Well-Being Index (WHO-5) | Assessing change between three time points: Change from baseline at 12-16 weeks, and change from 12-16 weeks at 6 months | ||
Secondary | Diabetes Distress Scale (DDS) | Assessing change between three time points: Change from baseline at 12-16 weeks, and change from 12- 16 weeks at 6 months | ||
Secondary | Glycosylated haemoglobin (HbA1c) | Assessing change between three time points: Change from baseline at 12-16 weeks, and change from 12-16 weeks at 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |